EMEA-001397-PIP06-17
Key facts
| Invented name |
Imbruvica
|
| Active substance |
Ibrutinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0297/2017
|
| PIP number |
EMEA-001397-PIP06-17
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of lymphoplasmacytic lymphoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Janssen-Cilag International N.V.
Tel. +32 1 464 1125 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|